Purple Biotech Ltd ADR (PPBT)

$0.71 -0.01 (-1.22%)
Market Cap 9.18M
Revenue (ttm) 0.00
Net Income (ttm) -7.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 63,900
Avg Vol 9,192,603
Day's Range N/A - N/A
Shares Out 12.85M
Stochastic %K 27%
Beta 0.60
Analysts Sell
Price Target $34.00

Company Profile

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 933 3121
Fax: 972 3 509 7196
Address:
4 Oppenheimer Street, Science Park, Rehovot, Israel
Stocktelligence
Stocktelligence Dec. 25 at 10:36 AM
$PPBT first post and then this? 🫠😶‍🌫️
0 · Reply
BlackMondayM
BlackMondayM Dec. 25 at 10:19 AM
$PPBT Forward momentum is increasingly dictated by operational clarity, as stakeholders scrutinize repeatability across reporting periods. Shortfalls would likely reprice expectations quickly.
0 · Reply
Stocktelligence
Stocktelligence Dec. 24 at 10:56 PM
$PPBT thx Izzy for the nice christmas
0 · Reply
Stocksavior14
Stocksavior14 Dec. 24 at 6:06 PM
$PPBT permabulls prepping their butt cheeks for the next REVERSE SPLIT while our management gets rich
0 · Reply
demo1one
demo1one Dec. 24 at 3:39 PM
$PPBT lol
1 · Reply
NMAY4
NMAY4 Dec. 23 at 8:21 PM
@MomentumZeus Hello, thanks for this opportunity. May I ask your thoughts on $PPBT. I have $0.8581 average. thanks.
1 · Reply
FullPorrtDipz
FullPorrtDipz Dec. 23 at 7:31 PM
If you like getting in them before the massive moves.. Drop @MomentumZeus a FOLLOW below. He's been calling some insane runners lately.. 🚀 Adds on $PPBT $ENVB $SIDU $CETX -
0 · Reply
Stocktelligence
Stocktelligence Dec. 23 at 6:28 PM
$PPBT
0 · Reply
Stocksavior14
Stocksavior14 Dec. 23 at 6:02 PM
$PPBT super mega bullish day in permabull land @Smitty61 @DrHims @YamiDawg @Mattblock hows everything going?
0 · Reply
LetItRip675
LetItRip675 Dec. 23 at 5:30 PM
$PPBT I need a cigarette
0 · Reply
Latest News on PPBT
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress

Dec 4, 2025, 7:00 AM EST - 21 days ago

Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress

Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 14, 2025, 8:00 AM EST - 5 weeks ago

Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update

Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

Oct 29, 2025, 7:33 AM EDT - 2 months ago

Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification

Oct 20, 2025, 4:00 PM EDT - 2 months ago

Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification

Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

Sep 5, 2025, 4:00 PM EDT - 3 months ago

Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 7:00 AM EDT - 4 months ago

Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Purple Biotech Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 7:00 AM EDT - 5 months ago

Purple Biotech Reports Second Quarter 2025 Financial Results

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

Jul 23, 2025, 7:00 AM EDT - 5 months ago

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

Jun 23, 2025, 7:00 AM EDT - 6 months ago

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

Purple Biotech Reports First Quarter 2025 Financial Results

May 21, 2025, 7:10 AM EDT - 7 months ago

Purple Biotech Reports First Quarter 2025 Financial Results

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

May 12, 2025, 7:30 AM EDT - 8 months ago

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

Apr 28, 2025, 8:28 AM EDT - 8 months ago

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Mar 10, 2025, 8:57 AM EDT - 10 months ago

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

Feb 18, 2025, 7:00 AM EST - 11 months ago

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 5, 2024, 7:13 AM EST - 1 year ago

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 3, 2024, 8:23 AM EST - 1 year ago

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Why Is Purple Biotech Stock Trading Higher On Monday?

Dec 2, 2024, 9:18 AM EST - 1 year ago

Why Is Purple Biotech Stock Trading Higher On Monday?

Purple Biotech Reports Third Quarter 2024 Financial Results

Nov 15, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Reports Third Quarter 2024 Financial Results

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Nov 4, 2024, 7:50 AM EST - 1 year ago

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 25, 2024, 7:20 AM EDT - 1 year ago

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 10, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Sep 18, 2024, 6:30 AM EDT - 1 year ago

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Aug 30, 2024, 7:00 AM EDT - 1 year ago

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 16, 2024, 8:12 AM EDT - 1 year ago

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

Jul 25, 2024, 7:35 AM EDT - 1 year ago

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

Jul 10, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Jul 2, 2024, 4:00 PM EDT - 1 year ago

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Jul 1, 2024, 9:00 AM EDT - 1 year ago

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Jun 27, 2024, 7:45 AM EDT - 1 year ago

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

Jun 1, 2024, 8:00 AM EDT - 1 year ago

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

Purple Biotech Reports First Quarter 2024 Financial Results

May 21, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech Reports First Quarter 2024 Financial Results

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Mar 14, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Mar 5, 2024, 7:55 AM EST - 1 year ago

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Feb 27, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Feb 13, 2024, 7:00 AM EST - 2 years ago

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Feb 1, 2024, 7:30 AM EST - 2 years ago

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

Dec 20, 2023, 8:05 AM EST - 2 years ago

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Dec 14, 2023, 6:50 AM EST - 2 years ago

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Purple Biotech Reports Third Quarter 2023 Financial Results

Nov 21, 2023, 6:50 AM EST - 2 years ago

Purple Biotech Reports Third Quarter 2023 Financial Results

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

Oct 19, 2023, 3:55 PM EDT - 2 years ago

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

Purple Biotech Announces $5 Million Registered Direct Offering

Oct 17, 2023, 8:00 AM EDT - 2 years ago

Purple Biotech Announces $5 Million Registered Direct Offering

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action

Oct 6, 2023, 7:50 AM EDT - 2 years ago

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

Oct 3, 2023, 7:50 AM EDT - 2 years ago

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

Purple Biotech Reports Second Quarter 2023 Financial Results

Aug 22, 2023, 9:29 AM EDT - 2 years ago

Purple Biotech Reports Second Quarter 2023 Financial Results

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

Jul 11, 2023, 8:15 AM EDT - 2 years ago

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

May 16, 2023, 4:00 PM EDT - 2 years ago

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors

Apr 19, 2023, 8:15 AM EDT - 2 years ago

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors

Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference

Apr 18, 2023, 7:00 AM EDT - 2 years ago

Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference

Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron

Mar 24, 2023, 7:00 AM EDT - 2 years ago

Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron

Stocktelligence
Stocktelligence Dec. 25 at 10:36 AM
$PPBT first post and then this? 🫠😶‍🌫️
0 · Reply
BlackMondayM
BlackMondayM Dec. 25 at 10:19 AM
$PPBT Forward momentum is increasingly dictated by operational clarity, as stakeholders scrutinize repeatability across reporting periods. Shortfalls would likely reprice expectations quickly.
0 · Reply
Stocktelligence
Stocktelligence Dec. 24 at 10:56 PM
$PPBT thx Izzy for the nice christmas
0 · Reply
Stocksavior14
Stocksavior14 Dec. 24 at 6:06 PM
$PPBT permabulls prepping their butt cheeks for the next REVERSE SPLIT while our management gets rich
0 · Reply
demo1one
demo1one Dec. 24 at 3:39 PM
$PPBT lol
1 · Reply
NMAY4
NMAY4 Dec. 23 at 8:21 PM
@MomentumZeus Hello, thanks for this opportunity. May I ask your thoughts on $PPBT. I have $0.8581 average. thanks.
1 · Reply
FullPorrtDipz
FullPorrtDipz Dec. 23 at 7:31 PM
If you like getting in them before the massive moves.. Drop @MomentumZeus a FOLLOW below. He's been calling some insane runners lately.. 🚀 Adds on $PPBT $ENVB $SIDU $CETX -
0 · Reply
Stocktelligence
Stocktelligence Dec. 23 at 6:28 PM
$PPBT
0 · Reply
Stocksavior14
Stocksavior14 Dec. 23 at 6:02 PM
$PPBT super mega bullish day in permabull land @Smitty61 @DrHims @YamiDawg @Mattblock hows everything going?
0 · Reply
LetItRip675
LetItRip675 Dec. 23 at 5:30 PM
$PPBT I need a cigarette
0 · Reply
Stocksavior14
Stocksavior14 Dec. 23 at 4:49 PM
$PPBT if anyone learned anything it’s VERY FEW of them… most retail shouldn’t be trading.. they don’t have the mental capacity to believe anything that goes against what they “hope” for. Just look at BOXL.. 3rd reverse split… and already crashing again… yep… that’s PPBTs future because we are too BROKE for a bio company and somehow they want to pay for and work on MULTIPLE DRUGS they can’t afford. It’s all to enrich themselves
0 · Reply
Smittysixty
Smittysixty Dec. 23 at 3:35 PM
$PPBT It’s been 594 days since NT‑219’s Phase 1/2 trial wrapped on May 8, 2024. So why is the final cohort — including the 100mg dose — still under wraps? Mgmt equity approved. Institutions loading. Pipeline stacked. Yet the data we’ve all been waiting for is still locked away. Facts over FUD: insiders don’t sit on results unless they’re timing the release. Question is… what’s the play?
0 · Reply
Smittysixty
Smittysixty Dec. 23 at 3:33 PM
$PPBT Yeah, Mor Research handed Purple Biotech first rights to their oncology puppies… just to watch the company go out of business. Makes total sense. Because that’s what top-tier research institutions do — partner with a team they think will fail. 🙃 Meanwhile, mgmt equity approved, institutions loading, and pipeline stacked. But sure, keep the clown show going. https://www.globenewswire.com/news-release/2023/01/03/2582013/0/en/Purple-Biotech-and-Mor-Research-Applications-Announce-Research-Collaboration-to-Identify-Promising-Investigational-Oncology-Treatments.html
0 · Reply
Smittysixty
Smittysixty Dec. 23 at 3:31 PM
$PPBT “Market cap makes sense now”? Sure — if you ignore the fact that Virtu, Citadel, Orca, Intercoastal, Lincoln and others just bought in. Wild how the same folks who’ve been warning for 2–3 years are still here… watching, posting, obsessing. Institutions are loading. Mgmt equity just got approved. Pipeline’s deeper than ever. But yeah, tell us again how it’s “finally fairly valued.” 🙃 https://fintel.io/so/us/ppbt
0 · Reply
Duediligence20
Duediligence20 Dec. 23 at 2:49 PM
$PPBT When is the last time our BOD or Management Team bought shares of Purple? Oh yeah, many many years ago! Scam Co.
0 · Reply
Purplepayday
Purplepayday Dec. 23 at 2:43 PM
$PPBT i wonder when the few bulls that’s left here will realize that the Market Cap already is making sense for this ticker .. So many warnings and negative post during the last 2-3 years and only to be ignored or blocked. Maybe some have learned sometimg from it all 🤷🏻‍♂️
0 · Reply
JuggernautRaider
JuggernautRaider Dec. 23 at 1:53 PM
$PPBT lock Gil up
0 · Reply
melissascrookedtooth
melissascrookedtooth Dec. 23 at 4:56 AM
$PPBT new update from the nt219 phase 2 trial site. the study has been lowered to 75mg dosage
2 · Reply
LuckyBoy27
LuckyBoy27 Dec. 22 at 8:52 PM
$PPBT ping pong 🏓
1 · Reply
Stocksavior14
Stocksavior14 Dec. 22 at 8:02 PM
$PPBT looks like even more of the permabulls have disappeared🤣🤣 Hey permabulls, how’d that recent PR about our pre-clinical drug work out?🤣🤣
0 · Reply
Stocktelligence
Stocktelligence Dec. 22 at 6:24 PM
$PPBT
0 · Reply
Stocksavior14
Stocksavior14 Dec. 22 at 5:37 PM
$PPBT what a scam this has been!! The bulls deserve every penny of loss for all their lies!
0 · Reply